Erasca (ERAS) EBIAT (2020 - 2026)
Erasca posted quarterly EBIAT of -$183.4 million for Q1 2026, down 492.39% year-on-year from $46.7 million in Q1 2025, and down 530.55% on a QoQ basis from -$29.1 million in Q4 2025.
Erasca (ERAS) has 7 years of EBIAT data on file, last reported at -$183.4 million in Q1 2026.
- For the quarter ending Q1 2026, EBIAT fell 492.39% year-over-year to -$183.4 million; the trailing twelve-month figure through Mar 2026 stood at -$277.0 million (down 75.78% YoY), and the FY2025 full-year result was -$124.5 million, up 22.95% from the prior year.
- EBIAT for Q1 2026 stood at -$183.4 million, down from -$29.1 million in the prior quarter.
- Across five years, EBIAT topped out at -$29.1 million in Q4 2025 and bottomed at -$183.4 million in Q1 2026.
- The 5-year median for EBIAT is -$33.2 million (2023), against an average of -$49.3 million.
- The widest annual swing landed in 2023, when EBIAT jumped 78.04%; it then plunged 492.39% in 2026.
- A 5-year view of EBIAT shows it stood at -$135.2 million in 2022, then surged by 78.04% to -$29.7 million in 2023, then fell by 8.52% to -$32.2 million in 2024, then grew by 9.74% to -$29.1 million in 2025, then sank by 530.55% to -$183.4 million in 2026.
- The last three EBIAT figures came in at -$183.4 million (Q1 2026), -$29.1 million (Q4 2025), and -$30.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | -183.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -183.44 Mn |
| Dec 31, 2025 | -29.09 Mn |
| Sep 30, 2025 | -30.61 Mn |
| Jun 30, 2025 | -33.88 Mn |
| Mar 31, 2025 | -30.97 Mn |
| Dec 31, 2024 | -32.23 Mn |
| Sep 30, 2024 | -31.20 Mn |
| Jun 30, 2024 | -63.20 Mn |
| Mar 31, 2024 | -35.02 Mn |
| Dec 31, 2023 | -29.70 Mn |
| Sep 30, 2023 | -30.36 Mn |
| Jun 30, 2023 | -31.78 Mn |
| Mar 31, 2023 | -33.20 Mn |
| Dec 31, 2022 | -135.25 Mn |
| Sep 30, 2022 | -35.49 Mn |
| Jun 30, 2022 | -35.61 Mn |
| Mar 31, 2022 | -36.46 Mn |
| Dec 31, 2021 | -30.46 Mn |
| Sep 30, 2021 | -46.07 Mn |
| Jun 30, 2021 | -28.21 Mn |
| Mar 31, 2021 | -18.02 Mn |
| Dec 31, 2020 | -61.90 Mn |
| Sep 30, 2020 | -10.61 Mn |
| Jun 30, 2020 | -5.49 Mn |